JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms (original) (raw)
- Letter
- Published: 15 March 2009
- Andrew Chase1,2,
- Richard T Silver3,
- David Oscier4,
- Katerina Zoi5,
- Y Lynn Wang3,
- Holger Cario6,
- Heike L Pahl7,
- Andrew Collins2,
- Andreas Reiter8,
- Francis Grand1,2 &
- …
- Nicholas C P Cross1,2
Nature Genetics volume 41, pages 446–449 (2009)Cite this article
- 2032 Accesses
- 315 Citations
- 22 Altmetric
- Metrics details
Abstract
Chronic myeloproliferative neoplasms (MPNs) are a group of related conditions characterized by the overproduction of cells from one or more myeloid lineages. More than 95% of cases of polycythemia vera, and roughly half of essential thrombocythemia and primary myelofibrosis acquire a unique somatic 1849G>T JAK2 mutation (encoding V617F) that is believed to be a critical driver of excess proliferation1,2,3,4. We report here that _JAK2_V617F-associated disease is strongly associated with a specific constitutional JAK2 haplotype, designated 46/1, in all three disease entities compared to healthy controls (polycythemia vera, n = 192, P = 2.9 × 10−16; essential thrombocythemia, n = 78, P = 8.2 × 10−9 and myelofibrosis, n = 41, P = 8.0 × 10−5). Furthermore, _JAK2_V617F specifically arises on the 46/1 allele in most cases. The 46/1 JAK2 haplotype thus predisposes to the development of _JAK2_V617F-associated MPNs (OR = 3.7; 95% CI = 3.1–4.3) and provides a model whereby a constitutional genetic factor is associated with an increased risk of acquiring a specific somatic mutation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
References
- James, C. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144–1148 (2005).
Article CAS Google Scholar - Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779–1790 (2005).
Article CAS Google Scholar - Levine, R.L. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387–397 (2005).
Article CAS Google Scholar - Baxter, E.J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054–1061 (2005).
Article CAS Google Scholar - Kralovics, R., Guan, Y. & Prchal, J.T. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp. Hematol. 30, 229–236 (2002).
Article CAS Google Scholar - Jones, A.V. et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106, 2162–2168 (2005).
Article CAS Google Scholar - Pikman, Y. et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 3, e270 (2006).
Article Google Scholar - Kralovics, R. Genetic complexity of myeloproliferative neoplasms. Leukemia 22, 1841–1848 (2008).
Article CAS Google Scholar - Rumi, E. et al. Disease anticipation in familial myeloproliferative neoplasms. Blood 112, 2587–2588 (2008).
Article CAS Google Scholar - Landgren, O. et al. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24, 577 first-degree relatives of 11, 039 patients with myeloproliferative neoplasms in Sweden. Blood 112, 2199–2204 (2008).
Article CAS Google Scholar - Pardanani, A., Fridley, B.L., Lasho, T.L., Gilliland, D.G. & Tefferi, A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 111, 2785–2789 (2008).
Article CAS Google Scholar - Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661–678 (2007).
- Stephens, M. & Donnelly, P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 73, 1162–1169 (2003).
Article CAS Google Scholar - Cario, H., Goerttler, P.S., Steimle, C., Levine, R.L. & Pahl, H.L. The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. Br. J. Haematol. 130, 800–801 (2005).
Article CAS Google Scholar - Barrett, J.C. et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40, 955–962 (2008).
Article CAS Google Scholar - Sandberg, E.M., Wallace, T.A., Godeny, M.D., VonDerLinden, D. & Sayeski, P.P. Jak2 tyrosine kinase: a true jak of all trades? Cell Biochem. Biophys. 41, 207–232 (2004).
Article Google Scholar - Khoury, M.J., Beaty, T.H. & Cohen, B.H. Fundamentals of Genetic Epidemiology (Oxford University Press, New York, 1993).
- Easton, D.F. et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447, 1087–1093 (2007).
Article CAS Google Scholar - Eeles, R.A. et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet. 40, 316–321 (2008).
Article CAS Google Scholar - Di Bernardo, M.C. et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat. Genet. 40, 1204–1210 (2008).
Article CAS Google Scholar - Jones, A.V. et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 107, 3339–3341 (2006).
Article CAS Google Scholar
Acknowledgements
This study was supported by Leukaemia Research (UK) Specialist Programme Grant 0280 and makes use (in part) of data generated by the WTCCC. A full list of the investigators who contributed to the generation of the WTCCC data are available from www.wtccc.org.uk, funding for which was provided by the Wellcome Trust under award 076113. We are grateful to P. Strike (Salisbury Research and Development Support Unit) for statistical advice. A.R. was supported by the Deutsche José Carreras Leukämie-Stiftung e.V. - DJCLS R06/02, Germany.
Author information
Authors and Affiliations
- Wessex Regional Genetics Laboratory, Salisbury, UK
Amy V Jones, Andrew Chase, Francis Grand & Nicholas C P Cross - Human Genetics Division, University of Southampton, UK
Amy V Jones, Andrew Chase, Andrew Collins, Francis Grand & Nicholas C P Cross - Weill Medical College of Cornell University, New York, New York, USA
Richard T Silver & Y Lynn Wang - Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK
David Oscier - Haematology Research Laboratory, Biomedical Research Foundation, Academy of Athens, Athens, Greece
Katerina Zoi - Department of Pediatrics and Adolescent Medicine, University Hospital Ulm, Ulm, Germany
Holger Cario - Department of Experimental Anaesthesiology, University Hospital Freiburg, Freiburg, Germany
Heike L Pahl - III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Germany
Andreas Reiter
Authors
- Amy V Jones
You can also search for this author inPubMed Google Scholar - Andrew Chase
You can also search for this author inPubMed Google Scholar - Richard T Silver
You can also search for this author inPubMed Google Scholar - David Oscier
You can also search for this author inPubMed Google Scholar - Katerina Zoi
You can also search for this author inPubMed Google Scholar - Y Lynn Wang
You can also search for this author inPubMed Google Scholar - Holger Cario
You can also search for this author inPubMed Google Scholar - Heike L Pahl
You can also search for this author inPubMed Google Scholar - Andrew Collins
You can also search for this author inPubMed Google Scholar - Andreas Reiter
You can also search for this author inPubMed Google Scholar - Francis Grand
You can also search for this author inPubMed Google Scholar - Nicholas C P Cross
You can also search for this author inPubMed Google Scholar
Contributions
The study was designed by A.V.J., A. Chase., F.G. and N.C.P.C. A.V.J. performed the laboratory analysis. R.T.S., D.O., K.Z., Y.L.W., H.L.P., H.C. and A.R. provided clinical samples and associated information. A.V.J., A. Chase, A. Collins and N.C.P.C. analyzed the data. N.C.P.C. wrote the first draft of the manuscript and all authors contributed to and approved the final version.
Corresponding author
Correspondence toNicholas C P Cross.
Supplementary information
Rights and permissions
About this article
Cite this article
Jones, A., Chase, A., Silver, R. et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.Nat Genet 41, 446–449 (2009). https://doi.org/10.1038/ng.334
- Received: 06 November 2008
- Accepted: 16 January 2009
- Published: 15 March 2009
- Issue Date: April 2009
- DOI: https://doi.org/10.1038/ng.334